Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass. (September 16, 2024) – Sirtex Medical (“Sirtex”), a leading manufacturer of interventional treatment solutions, today announced that it has received […]
Tag: Sirtex
Sirtex Medical and BlackSwan Vascular, Inc. announce first patient enrolled in pivotal LAVA Study
LAVA clinical trial underway for potential first FDA-approved liquid embolic system for a peripheral vascular indication WOBURN, Mass., April 19, 2021 /PRNewswire/ — Sirtex Medical (Sirtex), a leading manufacturer of targeted liver cancer therapies, and BlackSwan Vascular, Inc. (BlackSwan), a Bay Area-based private company […]
Sirtex Medical appoints Dr. Mark A. Turco as Global Chief Medical Officer and EVP of Research & Development
Industry veteran to lead Medical and Clinical Affairs to advance clinical trials and accelerate further development of cancer therapies WOBURN, Mass., June 3, 2020 /PRNewswire/ — Sirtex Medical US Holdings, Inc. (“Sirtex”), a leading manufacturer of targeted liver cancer therapies, announced the appointment of […]
Varian to Discuss Agreement to Acquire Sirtex
PALO ALTO, Calif., Jan. 30, 2018 /PRNewswire/ — Varian (NYSE: VAR) today announced that it will webcast a conference call to discuss the details of the agreement, also announced today, to acquire all the outstanding shares of Sirtex Medical. Sirtex is an Australia-based global […]
SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC
PUBLIC RELEASE: 22-APR-2017 April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and […]